



Emerging Influenza Viruses and Anti-influenza Vaccines

Guest Editors:

Dr. Pavel Volchkov

The National Medical Research
Center for Endocrinology, 117036
Moscow, Russia

Dr. Irina Isakova-Sivak

Department of Virology, Institute
of Experimental Medicine, 12
Acad. Pavlov Street, St
Petersburg, Russia

Deadline for manuscript
submissions:
closed (30 October 2023)

Message from the Guest Editors

Avian influenza is a highly contagious viral disease that affects various livestock, domestic, and wild animals. Outbreaks of avian influenza occur regularly on poultry farms around the world. The only way to contain the epidemic is to slaughter the entire poultry population that has come into contact with infected animals, resulting in severe economic losses. On the other hand, the greatest danger is that animal influenza viruses will be transmitted to humans. In this case, the appearance of a disease with unpredictable symptoms is possible.

It should be noted that the recent pandemic caused by another disease of zoonotic origin that started to spread from human to human—COVID-19—has clearly shown the need to find new ways to develop effective vaccines. As a result, new approaches to vaccine production have been actively developed. At the same time, it is generally accepted that influenza viruses pose a pandemic threat, which requires the development of effective ways to prevent infection.

This Special Issue will bring together original research papers or reviews dealing with research into emerging influenza viruses and new approaches to influenza prevention.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com